Streetbeat News

BRAXF

Braxia Scientific Corp

https://champignonbrands.com/

Industry

Outpatient Mental Health and Substance Abuse Centers

Open

0.00

Mkt cap

850K

Volume

9K

High

0.00

P/E Ratio

-0.07

52-wk high

0.01

Low

0.00

Div yield

N/A

52-wk low

0.00

Zappy Zapolin, a prominent figure in the psychedelics space, discusses his transformative experiences with psychedelics and their therapeutic potential. He has advised companies like KetaMD, acquired by Braxia Scientific (OTC:BRAXF), and co-founded Psycheceutical Bioscience (OTC:BWVI). Zapolin advocates for the legal accessibility of psychedelic medicines to treat conditions like PTSD and addiction.

Portfolio Pulse from Nina Zdinjak

August 13, 2024 | 6:04 pm

In the Benzinga Psychedelics Podcast, Zappy Zapolin discusses the future of psychedelics, highlighting the industry's potential mainstream breakthrough in 2024 with federal legalization of MDMA for PTSD, psychedelics legalization campaigns, and COMPASS Pathways' commercialization. Zapolin, involved with companies like KetaMD (acquired by Braxia Scientific, OTC:BRAXF) and Psycheceutical Bioscience (OTC:BWVI), also launches guided psychedelic retreats, emphasizing the importance of medical supervision in therapy.

Portfolio Pulse from Lara Goldstein

February 29, 2024 | 4:04 pm

Braxia Scientific Corp. (OTC:BRAXF) reported its Q2 2024 financial results with a year-over-year increase in revenue and a significant decrease in operating expenses and net loss. Despite the improved performance, the company's CEO, Dr. Roger McIntyre, expressed concerns about insufficient funds to sustain operations and has initiated a process to explore strategic alternatives, including a potential sale, merger, or other significant transaction. The company also announced the resignation of board director Olga Cwiek and CFO Stephen Brooks, with Peter Rizakos appointed to the board and as CFO.

Portfolio Pulse from Lara Goldstein

December 04, 2023 | 8:09 pm

Several mergers and acquisitions have been announced in the psychedelics sector. Cybin (NYSE:CYBN) is acquiring Small Pharma (OTC:DMTTF), Silo Wellness (OTC:SILFF) is buying NUGL Inc./Kaya Group (OTC:NUGL), and Mindset Pharma (OTC:MSSTF) is being acquired by Otsuka America Inc., part of Otsuka Holdings (OTC:OTSKF). Additionally, Psyched Wellness (OTC:PSYCF) is set to receive $7.5M in financing. The AdvisorShares Psychedelics ETF (NYSE:PSIL) has seen a slight increase in its share price.

Portfolio Pulse from Lara Goldstein

September 05, 2023 | 2:08 pm

Braxia Scientific Corp. (OTC:BRAXF) reported a Q1 net loss of $592,785, an 18% decrease from the same period in 2022. The company's cash held as of June 30, 2023, was $636,483, compared to $5.67 million by June 30, 2022. Despite the financial challenges, the company saw a 44% YoY increase in revenue and a 17% decrease in operating expenses. CEO Dr. Roger McIntyre mentioned that the company is facing challenges in accessing capital through public markets and is considering alternative sources of capital and partnerships.

Portfolio Pulse from Lara Goldstein

August 31, 2023 | 1:28 pm

The Energia Foundation is hosting a psychedelics education event in Dubai, while new research finds a key receptor for treating depression with psychedelics. Creso Pharma (OTC:COPHF) signs an LOI for importing Swiss MDMA and psilocybin therapeutics to Australia. AdvisorShares Psychedelics ETF (NYSE:PSIL) shows a consistent upward trend.

Portfolio Pulse from Lara Goldstein

June 13, 2023 | 2:31 pm

BetterLife Pharma's non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies for Major Depressive Disorder. Braxia Scientific reports a 26.2% YoY growth in treatment volumes and plans to restructure its business, including slowing down its U.S.-based telemedicine business KetaMD.

Portfolio Pulse from Lara Goldstein

June 09, 2023 | 8:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.